PRACA PRZEGLĄDOWA
Pharmacological treatment of idiopathic retroperitoneal fibrosis
Więcej
Ukryj
1
Department of Internal Medicine and Rheumatology, Military Institute of Medicine – National Research Institute, Warsaw, Poland
Data nadesłania: 29-05-2025
Data ostatniej rewizji: 01-09-2025
Data akceptacji: 30-09-2025
Data publikacji online: 10-06-2026
Autor do korespondencji
Adrianna Niksińska
Department of Internal Medicine and Rheumatology, Military Institute of Medicine – National Research Institute,
128 Szaserów St., 04141 Warsaw, Poland
SŁOWA KLUCZOWE
DZIEDZINY
STRESZCZENIE
Idiopathic retroperitoneal fibrosis (IRF) is a rare disease characterized by inflammatory infiltration around the aorta, which can lead to clinical symptoms and complications, the most common of which is ureteral obstruction, potentially resulting in secondary renal failure.
A search of medical databases was conducted to compile a review article summarizing the immunosuppressive treatment options for IRF.
In addition to urological treatment, immunosuppressive drugs are used in the treatment of retroperitoneal fibrosis. The cornerstone of therapy remains glucocorticosteroids (GCs), whose effectiveness and relatively rapid effect have been proven. However, the issue of frequent disease relapses after discontinuation of GCs still remains, prompting clinicians to investigate the effectiveness of other immunosuppressive agents.
The efficacy of numerous immunosuppressive and biological medications in the treatment of IRF has been demonstrated in several studies; however, studies involving larger patient groups are still needed.
REFERENCJE (50)
1.
Vaglio A, Maritati F. Idiopathic retroperitoneal fibrosis. J Am Soc Nephrol 2016; 27: 1880–1889, DOI: 10.1681/ASN.2015101110.
2.
Fenaroli P, Maritati F, Vaglio A. Into clinical practice: diagnosis and therapy of retroperitoneal fibrosis. Curr Rheumatol Rep 2021; 23: 18, DOI: 10.1007/s11926-020-00966-9.
3.
Kermani TA, Crowson CS, Achenbach SJ, Luthra HS. Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes. Mayo Clin Proc 2011, 86: 297–303, DOI: 10.4065/mcp.2010.0663.
4.
Corradi D, Maestri R, Palmisano A, et al. Idiopathic retroperitoneal fibrosis: clinicopathologic features and differential diagnosis. Kidney Int 2007; 72: 742–753, DOI: 10.1038/sj.ki.5002427.
5.
Tanaka T, Masumori N. Current approach to diagnosis and management of retroperitoneal fibrosis. Int J Urol 2020; 27: 387–394, DOI: 10.1111/iju.14218.
6.
Razok A, Romero Noboa ME, Sami F, et al. IgG4-related disease and isolated retroperitoneal fibrosis: a narrative review. ARP Rheumatol 2023; 2: 155–159.
7.
Choi YK, Yang JH, Ahn SY, et al. Retroperitoneal fibrosis in the era of immunoglobulin G4-related disease. Kidney Res Clin Pract 2019; 38: 42–48, DOI: 10.23876/j.krcp.18.0052.
8.
Wang K, Wang Z, Zeng Q, et al. Clinical characteristics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One 2021; 16: e0245601, DOI: 10.1371/journal.pone.0245601.
9.
Bakir B, Yilmaz F, Turkay R, et al. Role of diffusion-weighted MR imaging in the differentiation of benign retroperitoneal fibrosis from malignant neoplasm: preliminary study. Radiology 2014; 272: 438–445, DOI: 10.1148/radiol.14131565.
10.
Fry AC, Singh S, Gunda SS, et al. Successful use of steroids and ureteric stents in 24 patients with idiopathic retroperitoneal fibrosis: a retrospective study. Nephron Clin Pract 2008; 108: c213–20, DOI: 10.1159/000119715.
11.
Van Bommel EFH, Siemes C, Hak LE, et al. Long-term renal and patient outcome in idiopathic retroperitoneal fibrosis treated with prednisone. Am J Kidney Dis 2007; 49: 615–625, DOI: 10.1053/j.ajkd.2007.02.268.
12.
Morin G, Mageau A, Benali K, et al. Persistent FDG/PET CT uptake in idiopathic retroperitoneal fibrosis helps identifying patients at a higher risk for relapse. Eur J Intern Med 2019; 62: 67–71, DOI: 10.1016/j.ejim.2019.01.019.
13.
Azizi M, Zajjari Y, Rafik H, El Kabbaj D. Retroperitoneal fibrosis in the military hospital of Morocco. Saudi J Kidney Dis Transpl 2020; 31: 169–175, DOI: 10.4103/1319-2442.279937.
14.
Scheel PJJ, Piccini J, Rahman MH, et al. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis. J Urol 2007; 178: 140–144, DOI: 10.1016/j.juro.2007.03.057.
15.
Adler S, Lodermeyer S, Gaa J, Heemann U. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. Rheumatology (Oxford) 2008; 47: 1535–1538, DOI: 10.1093/rheumatology/ken291.
16.
Scheel PJ Jr, Feeley N, Sozio SM. Combined prednisone and mycophenolate mofetil treatment for retroperitoneal fibrosis: a case series. Ann Intern Med 2011; 154: 31–36, DOI: 10.7326/0003-4819-154-1-201101040-00005.
17.
Obrenčević K, Petrović D, Aleksić P, et al. Successful treatment of idiopathic retroperitoneal fibrosis with combined immunosuppressive therapy. Vojnosanit Pregl 2019; 76: 1014–1021, DOI: 10.2298/VSP170714008O.
18.
Marcolongo R, Tavolini IM, Laveder F, et al. Immunosuppressive therapy for idiopathic retroperitoneal fibrosis: a retrospective analysis of 26 cases. Am J Med 2004; 116: 194–197, DOI: 10.1016/j.amjmed.2003.08.033.
19.
Prucha M, Kolombo I, Stadler P. Combination of steroids and azathioprine in the treatment of Ormond’s disease – a single centre retrospective analysis. Prague Med Rep 2016; 117: 34–41, DOI: 10.14712/23362936.2016.3.
20.
Alberici F, Palmisano A, Urban M, et al. Methotrexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 2013 72: 1584–1586, DOI: 10.1136/annrheumdis-2013-203267.
21.
Vianello F, Gargarella R, Cinetto F, et al. Usefulness of methotrexate in relapsing idiopathic retroperitoneal fibrosis. Clin Exp Rheumatol 2023; 41: 1544–1547, DOI: 10.55563/clinexprheumatol/atxzl5.
22.
Steimer A, O. Becker M. Treatment approaches for idiopathic retroperitoneal fibrosis: a systematic review with meta-analysis. BMC Rheumatol 2025, 9: 12. DOI: 10.1186/s41927-024-0045-z.
23.
Carey C, Gurumurthy G, Napier-Hemy R, Zelhof B. A review of the current treatment methods for retroperitoneal fibrosis with obstructive uropathy. BJUI Compass 2024; 5: 721–731, DOI: 10.1002/bco2.371.
24.
Van Bommel EFH, Pelkmans LG, Van Damme H, Hendriksz TR. Long-term safety and efficacy of a tamoxifen-based treatment strategy for idiopathic retroperitoneal fibrosis. Eur J Intern Med 2013; 444–450, DOI: 10.1016/j.ejim.2012.11.010.
25.
Brandt AS, Kamper L, Kukuk S, et al. Tamoxifen monotherapy in the treatment of retroperitoneal fibrosis. Urol Int 2014; 93: 320–325, DOI: 10.1159/000357814.
26.
Vaglio A, Palmisano A, Alberici F, et al. Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomized controlled trial. Lancet 2011; 378: 338–346, DOI: 10.1016/S0140-6736(11)60934-3.
27.
Van der Bilt FE, Hendriksz TR, van der Meijden WAG, et al. Outcome in patients with idiopathic retroperitoneal fibrosis treated with corticosteroid or tamoxifen monotherapy. Clin Kidney J 2016: 9: 184–191, DOI: 10.1093/ckj/sfv148.
28.
Brandt AS, Kamper L, Kukuk S, et al. An aid to decision-making in therapy of retroperitoneal fibrosis: dynamic enhancement analysis of gadolinium MRI. J Clin Med Res 2013; 5: 49–56, DOI: 10.4021/jocmr1254e.
29.
Gao H, Liu S, Mai Y, et al. Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis. Ann Rheum Dis 2023; 82: 688–697, DOI: 10.1136/ard-2022-223736.
30.
Oztas M, Altun I, Ayla AY, et al. Rituximab in the management of retroperitoneal fibrosis: a single tertiary rheumatology care center experience. Int J Rheum Dis 2023; 26: 1714–1721, DOI: 10.1111/1756-185X.14798.
31.
Boyeva V, Alabsi H, Seidman MA, et al. Use of rituximab in idiopathic retroperitoneal fibrosis. BMC Rheumatol 2020; 4: 40, DOI: 10.1186/s41927-020-00140-9.
32.
Wang A, Peng L, Zhou J, et al. Pilot study of tocilizumab monotherapy for active chronic periaortitis. RMD Open 2023; 9: e003007, DOI: 10.1136/rmdopen-2023-003007.
33.
Pierre S, Cordy PE, Razvi H. Retroperitoneal fibrosis: a case report of spontaneous resolution. Clin Nephrol 2002; 57: 314–319, DOI: 10.5414/cnp57314.
34.
Benson JR, Baum M. Tamoxifen for retroperitoneal fibrosis. Lancet 1993; 341: 836, DOI: 10.1016/0140-6736(93)90618-q.
35.
Garvin S, Dabrosin C. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo. Cancer Res 2003; 63: 8742–8748.
36.
Johannesdottir SA, Horvath-Puho E, Dekkers OM, et al. Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 2013; 173: 743–752, DOI: 10.1001/jamainternmed.2013.122.
37.
Decensi A, Maisonneeuve P, Rotmensz N, et al. Effect of tamoxifen on venous thromboembolic events in a breast cancer prevention trail. Circulation 2005; 650–656, DOI: 10.1161/01.CIR.0000154545.84124.AC.
38.
Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004; 141: 764–770, DOI: 10.7326/0003-4819-141-10-200411160-00007.
39.
Goncalves RG, Biato MA, Colosimo RDG, et al. Effects of mycophenolate mofetil and lisinopril on collagen deposition in unilateral ureteral obstruction in rats. Am J Nephrol 2004; 24: 527–536, DOI: 10.1159/000081706.
40.
Morath C, Schwenger V, Beimler J, et al. Antifibrotic actions of mycophenolic acid. Clin Transplant 2006: 20 Suppl 17: 25–29, DOI: 10.1111/j.1399-0012.2006.00597.x.
41.
Scheel PJ Jr, Feeley N. Retroperitoneal fibrosis. Rheum Dis Clin North Am 2013; 39: 365–381, DOI: 10.1016/j.rdc.2013.02.004.
42.
Mertens S, Zeegers AG, Wertheimer PA, et al. Efficacy and complications of urinary drainage procedures in idiopathic retroperitoneal fibrosis complicated by extrinsic ureteral obstruction. Int J Urol 2014; 21: 283–288, DOI: 10.1111/iju.12234.
43.
Wallwork R, Wallace Z, Perugino C, et al. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Medicine 2018; 97: 42. DOI: 10.1097/MD.0000000000012631.
44.
Pelkmans LG, Aarnoudse AJLH, Hendriksz TR, van Bommel EFH. Value of acute-phase reactants in monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Nephrol Dial Transplant 2012; 27: 2819–2825, DOI: 10.1093/ndt/gfr779.
45.
Magrey MN, Husni ME, Kushner I, Calabrese LH. Do acute-phase reactants predict response to glucocorticoid therapy in retroperitoneal fibrosis? Arthritis Rheum 2009; 61: 674–679, DOI: 10.1002/art.24461.
46.
Buttini EA, Maritati F, Vaglio A. [18F]-Fluorodeoxyglucose positron emission tomography and response to therapy in idiopathic retroperitoneal fibrosis. Eur Urol 2018; 73: 145–146, DOI: 10.1016/j.eururo.2017.09.024.
47.
Jansen I, Hendriksz TR, Han SH, et al. (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) for monitoring disease activity and treatment response in idiopathic retroperitoneal fibrosis. Eur J Intern Med 2010; 21: 216–221, DOI: 10.1016/j.ejim.2010.02.008.
48.
Piccoli GB, Consiglio V, Arena V, et al. Positron emission tomography as a tool for the ‘tailored’ management of retroperitoneal fibrosis: a nephron-urological experience. Nephrol Dial Transplant 2010; 25: 2603–2610, DOI: 10.1093/ndt/gfq051.
49.
Vaglio A, Greco P, Filice A, et al. Post-treatment residual tissue in idiopathic retroperitoneal fibrosis: active residual disease or silent “scar”? A study using 18F-fluorodeoxyglucose positron emission tomography. Clin Exp Rheumatol 2005; 23: 231–234.
50.
Raffiotta F, da Silva Escoli R, Quaglini S, et al. Idiopathic retroperitoneal fibrosis: long-term risk and predictors of relapse. Am J Kidney Dis 2019; 74: 742–750, DOI: 10.1053/j.ajkd.2019.04.020.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (
https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.